Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
暂无分享,去创建一个
J. Taube | C. Harview | R. Dummer | D. Elashoff | R. Pierce | M. Hellmann | P. Munster | A. Daud | M. Rosenblum | O. Hamid | M. Krummel | A. Algazi | P. Boasberg | B. Chmielowski | E. Garon | P. Tumeh | I. Shintaku | E. Taylor | T. Grogan | S. Goldinger | M. Gubens | P. J. Sanchez | Andrew Tucker | Jimmy Hwang | J. C. Osorio | D. L. Nguyen-Kim | Adi Nosrati | Jeremy Chang | K. Loo | N. Handley | K. Tsai | E. Sosa | J. C. Osorio | N. Khurana | N. Banayan
[1] S. Elledge,et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.
[2] J. Wolchok,et al. Targeting T Cell Co-receptors for Cancer Therapy. , 2016, Immunity.
[3] Antoni Ribas,et al. The “cancer immunogram” , 2016, Science.
[4] J. Wolchok,et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.
[5] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[6] K. Steele,et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. , 2016, The Lancet. Oncology.
[7] Jason B. Williams,et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.
[8] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[9] Wei Zhou,et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.
[10] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[11] J. Wolchok,et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. , 2015 .
[12] A. Daud,et al. Clinical characteristics predictive of response to pembrolizumab in advanced melanoma. , 2015 .
[13] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[14] T. Gajewski,et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.
[15] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[16] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[17] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[18] J. Lunceford,et al. Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome , 2014 .
[19] Antoni Ribas,et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.
[20] J. Taube,et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.
[21] P. Kubes,et al. Immune surveillance by the liver , 2013, Nature Immunology.
[22] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[23] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[24] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[25] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[26] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[27] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[28] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[29] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. Pierce,et al. Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells. , 2010, Gastroenterology.
[31] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[32] F. Momburg,et al. Cross‐presentation of oral antigens by liver sinusoidal endothelial cells leads to CD8 T cell tolerance , 2005, European journal of immunology.
[33] B. John,et al. Passive and Active Mechanisms Trap Activated CD8+ T Cells in the Liver1 , 2004, The Journal of Immunology.
[34] A. Livingstone,et al. Cutting Edge: CD4+ T Cell Help Can Be Essential for Primary CD8+ T Cell Responses In Vivo 1 , 2003, The Journal of Immunology.
[35] I. N. Crispe,et al. Hepatic T cells and liver tolerance , 2003, Nature Reviews Immunology.
[36] R. Calne. Immunological tolerance: the liver effect , 2002, Immunological reviews.
[37] H. Ljunggren,et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance , 2000, Nature Medicine.
[38] Wei Li,et al. Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. , 1997, Journal of immunology.
[39] R. Calne. Mechanisms in the acceptance of organ grafts. , 1976, British medical bulletin.
[40] R. Binns,et al. Induction of Immunological Tolerance by Porcine Liver Allografts , 1969, Nature.
[41] HARVEY M. CANTOR,et al. Hepatic Suppression of Sensitization to Antigen absorbed into the Portal System , 1967, Nature.